Advertisement

AAPS PharmSci

, Volume 4, Issue 4, pp 243–250 | Cite as

The prediction of plasma and brain levels of 2,3,5,6-tetramethylpyrazine following transdermal application

  • Xiaohong Qi
  • Chrisita Ackermann
  • Duxin Sun
  • Rong (Ron) Liu
  • Minli Sheng
  • Huimin Hou
Article

Abstract

The purpose of this study was to construct a pharmacokinetic (PK) model and to determine PK parameters of 2,3,5,6-tetramethylpyrazine (TMP) after application of TMP transdermal delivery system. Data were obtained in Sprague-Dawley (SD) rats following a single dose of TMP transdermal delivery system. Blood samples were obtained at 0, 0.25, 0.5, 1, 2, 4, 6, 16, and 24 hours after the transdermal application. In the brain level study, 18 SD rats were divided into 6 groups. Three SD rats before and after transdermal application were culled and sacrificed at each of the following time intervals: 2, 4, 6, 16, and 24 hours after the TMP-TTS application. TMP concentrations in plasma and brain tissues were determined using high performance liquid chromatography and data were fitted using a zero-order absorption and a firstorder-elimination 3-compartment PK model. Fitted parameters included 2 volumes of distribution (V1, V2) and 2 elimination rate constants (k10, k20). The elimination half-life for TMP in plasma and brain was 26.5 and 31.2 minutes, respectively. The proposed PK model fit observed concentrations of TMP very well. This model is useful for predicting drug concentrations in plasma and brain and for assisting in the development of transdermal systems.

Keywords

tetramethylpyrazine percutaneous absorption transdermal drug delivery system in vitro/in vivo pharmacokinetic model 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guo SK, Chen KJ, Qian ZH, Weng WL, Qian MY. Tetramethylpyrazine in the treatment of cardiovascular and cerebrovascular diseases. Planta Med. 1983;47:89.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen KJ, Chen K. Ischemic stroke treated with Ligusticum chuanxiong. Chin Med J (Engl) 1992;105(10):870–3.Google Scholar
  3. 3.
    Watanabe H. Candidates for cognitive enhancer extracted from medicinal plants: paeoniflorin and tetramethylpyrazine. Behav Brain Res. 1997;83:138–141.CrossRefGoogle Scholar
  4. 4.
    Liang CC, Hong CY, Chen CF, Tsai TH. Measurement and pharmacokinetic study of tetramethylpyrazine in rat blood and its regional brain tissue by high-performance liquid chromatography. J Chromatogr B Biomed Sci Applic. 1999;724(2):303–309.CrossRefGoogle Scholar
  5. 5.
    Tsai T, Liang C. Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis. Int J Pharm. 2001;216(1–2):61–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Cai W, Dong SN, Lou YQ. HPLC determination of tetramethylpyrazine in human serum and its pharmacokinetic parameters [in Chinese with English abstract]. Acta Pharm Sinica. 1989;24(12):881–886.Google Scholar
  7. 7.
    Lou YQ, Zhang H, Cao X, Chen ML. The pharmacokinetics and disposition of tetramethylpyrazine phosphate in dogs and rats [in Chinese with English abstract]. Acta Pharm Sinica. 1986;21(7):481–487.Google Scholar
  8. 8.
    Sun BL. Clinical use of tetramethylpyrazine: a review [in Chinese] Chin J Integr Tradit West Med. 1994;14:465–468.Google Scholar
  9. 9.
    Jia WC. Gao Yao Fang Ji. Beijing, China: Peoples Public Health Publisher, 1957.Google Scholar
  10. 10.
    Wang GQ. Zhong Guo Gao Yao Xue. Xian, China: Science and Technology Publisher; 1981:111–154.Google Scholar
  11. 11.
    Brown L, Langer R. Transdermal delivery of drugs. Annu Rev Med. 1988;39:221–229.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen KJ March of Integration of TCM and WM Towards 21st Century [in Chinese]. Beijing, China: Medicine Pharmaceutics Science-Technology Publisher, 1991:207–216.Google Scholar
  13. 13.
    Guy RH, Hadgraft J. Selection of drug candidates for transdermal delivery. In: Hadgraft J, Guy RH, eds. Transdermal Drug Delivery: Development Issues and Research Initiatives. New York, NY: Marcel Dekker, 1989:59–81.Google Scholar
  14. 14.
    Flynn GL, Stewart B. Percutaneous drug penetration: choosing candidates for transdermal development. Drug Dev Res. 1988;13:169–185.CrossRefGoogle Scholar
  15. 15.
    Qi XH, Hou HM. Transdermal delivery system of tetramethylpyrazine: the influence of varied EVA copolymer membrane on skin permeation of TMP. In: CRS-CPA Joint Workshop on Recent Advances in Drug Delivery Science and Technology, Beijing, September 20–22, China. 1997:48.Google Scholar
  16. 16.
    Qi XH. In Vitro and In Vivo Skin Permeation Study of Chuanxiong [dissertation]. Shanghai, China: Shanghai Institute of Industrial Pharmaceutics, 1999.Google Scholar
  17. 17.
    Matsuyama K, Nakashima M, Ichikawa M, Goto S. In vivo microdialysis for the transdermal absorption of valproate in rats. Biol Pharm Bull. 1994;17(10):1395–1398.CrossRefPubMedGoogle Scholar
  18. 18.
    Matsuyama K, Nakashima M, Ichikawa M, Goto S. Application of in vivo microdialysis to transdermal absorption of methotrexate in rats. Pharm Res. 1994;11(5):684–686.CrossRefPubMedGoogle Scholar
  19. 19.
    Bradley CR, Almirez RG, Conner DP, Rhyne PR, Peck CC. Noninvasive transdermal chemical collection, II: in vitro and in vivo skin permeability studies. Skin Pharmacol. 1990;3(4):227–235.CrossRefPubMedGoogle Scholar
  20. 20.
    Ritschel W, Starzacher A., Sabouni A, Hussain AS, Koch HP. Percutaneous absorption of rosmarinic acid in the rat. Methods Find Exp Clin Pharmacol. 1989;11(5):345–352.PubMedGoogle Scholar
  21. 21.
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982.Google Scholar
  22. 22.
    Tamai I, Tsuji A. Drug delivery through the blood-brain barrier. Adv Drug Deliv Rev. 1996;9(3):401–424.CrossRefGoogle Scholar
  23. 23.
    Chen X, Dong SN. Studies on the metabolites of tetramethylpyrazine in rabbits [in Chinese with English abstract]. Acta Pharm Sinica. 1996;31(8):617–621.Google Scholar
  24. 24.
    Li M, Handa S, Ikeda Y, Goto S. Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine Chuanxiong, on platelet thrombus formation under high shear rates. Thromb Res. 2001;104(1):15–28.CrossRefPubMedGoogle Scholar
  25. 25.
    Win Nonlin, Version 2.1., Palo Alto, CA. Pharsight Corporation. 1994.Google Scholar
  26. 26.
    Guy RH, Hadgraft J. The prediction of plasma levels of drugs following transdermal application. J Control Release. 1985;1:177–182.CrossRefGoogle Scholar
  27. 27.
    Guy RH, Hadgraft J. Interpretation and prediction of the kinetics of transdermal drug delivery: oestradiol, hyoscine, and timolol. Int J Pharm. 1986;32:159–163.CrossRefGoogle Scholar
  28. 28.
    Watanabe H. Candidates for cognitive enhancer extracted from medicinal plants: paeoniflorin and tetramethylpyrazine. Behav Brain Res. 1997;83:138–141.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2002

Authors and Affiliations

  • Xiaohong Qi
    • 1
  • Chrisita Ackermann
    • 2
  • Duxin Sun
    • 3
  • Rong (Ron) Liu
    • 1
  • Minli Sheng
    • 4
  • Huimin Hou
    • 5
  1. 1.Global Product Development, Bristol-Myers SquibbWorldwide Consumer MedicinesHillside
  2. 2.School of PharmacyUniversity of MichiganAnn Arbor
  3. 3.Pharmaceutical Research InstituteBristol-Myers SquibbNew Brunswick
  4. 4.Medical Radiology Research Institute, School of MedicineFudan UniversityShanghaiPeople's Republic of China
  5. 5.Shanghai Institute of Industrial PharmaceuticsNational Pharmaceutical Engineering Research CenterShanghaiPeople's Republic of China

Personalised recommendations